Gene expression assay in the management of early breast cancer

Research output: Contribution to journalReview articlepeer-review


The addition of adjuvant chemotherapy to hormonal therapy is often considered ques-tionable in patients with estrogen receptor-positive early breast cancer. Low risk of disease relapse after endocrine treatment alone and/or a low sensitivity to chemotherapy are reasons behind not all patients benefit from chemotherapy. Most of the patients could be exposed to unnecessary treat-ment-related adverse events and health care costs when treatment decision-making is based only on classical clinical histological features. Gene expression profile has been developed to refine physi-cian’s decision-making process and to tailor personalized treatment to patients. In particular, these tests are designed to spare patients the side effects of unnecessary treatment, and ensure that adju-vant chemotherapy is correctly recommended to patients with early breast cancer. In this review, we will discuss the main diagnostic tests and their potential clinical applications (Oncotype DX, MammaPrint, PAM50/Prosigna, EndoPredict, MapQuant Dx, IHC4, and Theros-Breast Cancer Gene Expression Ratio Assay).

Original languageEnglish
Pages (from-to)2826-2839
Number of pages14
JournalCurrent Medicinal Chemistry
Issue number17
Publication statusPublished - 2020


  • Adjuvant chemotherapy
  • Early breast cancer (EBC)
  • Estrogen receptor positive (ER)
  • MapQuant Dx
  • Oncotype DX

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Organic Chemistry


Dive into the research topics of 'Gene expression assay in the management of early breast cancer'. Together they form a unique fingerprint.

Cite this